Premium
Acute leukemia following treatment of polycythemia vera and essential thrombocythemia with uracil mustard
Author(s) -
Toh Ban T.,
Gregory Stephanie A.,
Knospe William H.
Publication year - 1988
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830280113
Subject(s) - polycythemia vera , medicine , essential thrombocythemia , thrombocytosis , myelofibrosis , gastroenterology , leukemia , acute leukemia , stomatitis , surgery , platelet , bone marrow
Transformation to acute leukemia (AL) is known to occur in polycythemia Vera (PV) and essential thrombocythemia (ET). Myelosuppressive therapy with agents such as 32 P and alkylating agents increase this risk in both disorders. The alkylating agent, uracil mustard (UM), which is an effective agent for controlling thrombocytosis, has not been reported to be leukemogenic. We have treated 29 patients with UM (9 treated continuously and 20 treated intermittently): II with PV, 16 with ET, and 2 with myelofibrosis (MF). Three patients developed AL, two after continuous therapy. These two patients with PV had received the fourth highest and highest total dose of UM, and their duration of treatment was the third and fourth longest among the nine patients treated continuously, respectively. One out of 20 patients treated intermittently with UM developed AL. This patient (3) with ET had received the highest total dose of UM, and her duration of treatment was the longest among the 20 patients treated intermittently.